Advertisement

Regadenoson long-lasting use induced tachyarrythmia

  • Carlos Ramos-FontEmail author
  • Amelia Jimenez-Heffernan
  • Antonio González Jimenez
  • Mahsa Rashki
  • Jose Manuel Llamas Elvira
Images that Teach
  • 28 Downloads

Notes

Disclosures

C. Ramos-Font, A. Jimenez-Heffernan, A. Gonzalez, M. Rashki and J. M. Llamas-Elvira work for the public health system and they have nothing to disclose. They have no funding resources nor conflict of interest in this publication.

References

  1. 1.
    Salgado-García C, Jiménez-Heffernan A, Ramos-Font C, Lopez-Martin J, Sánchez-de-Mora E, Aroui T, et al. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease. Rev Esp Med Nucl Imagen Mol 2016;35:283-6.Google Scholar
  2. 2.
    LEXISCAN (regadenoson) injection for intravenous use. highlights of prescribing information. FDA Reference ID 4041701. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022161s013lbl.pdf.
  3. 3.
    Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.CrossRefGoogle Scholar
  4. 4.
    Ertek S, Cicero AF. Hyperthyroidism and cardiovascular complications: A narrative review on the basis of pathophysiology. Arch Med Sci 2013;9:944-52.CrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2018

Authors and Affiliations

  • Carlos Ramos-Font
    • 1
    Email author
  • Amelia Jimenez-Heffernan
    • 2
  • Antonio González Jimenez
    • 1
  • Mahsa Rashki
    • 1
  • Jose Manuel Llamas Elvira
    • 1
  1. 1.Nuclear Medicine DepartmentHospital Universitario Virgen de las NievesGranadaSpain
  2. 2.Nuclear Medicine DepartmentHospital Juan Ramon JimenezHuelvaSpain

Personalised recommendations